Does Metformin Have an Effect on Stent Patency Rates

Area of Science:

• Vascular Surgery
• Endovascular Interventions
• Pharmacology

Background:

• Metformin is a widely used medication for type 2 diabetes.
• Existing research suggests metformin offers endothelial protection by reducing vascular reactivity.
• This study investigated metformin's potential to reduce restenosis and reintervention after lower extremity non-drug-eluting stent (nDES) placement.

Purpose of the Study:

• To evaluate the efficacy of metformin in preventing restenosis and reintervention in patients undergoing nDES procedures in the superficial femoral artery (SFA) and/or popliteal artery.
• To compare restenosis, reintervention, and limb loss rates among different patient groups based on metformin use or dosage.
• To assess the impact of metformin on vascular outcomes in peripheral artery disease treated with nDES.

Main Methods:

• A retrospective study of 187 patients who received SFA/popliteal nDES between October 2012 and December 2015.
• Patients were stratified into three groups for comparison of duplex-based restenosis (>60%), limb loss, and reintervention rates.
• Follow-up included duplex ultrasound assessments at regular intervals to monitor stent patency.

Main Results:

• The study included 187 patients (123 male, 64 female) with an average age of 64.65 years.
• The primary indications for intervention were claudication and critical limb-threatening ischemia.
• No statistically significant differences were observed in limb loss, restenosis, or reintervention rates among the three groups.

Conclusions:

• Metformin, despite its known endothelial protective effects, did not demonstrate a significant reduction in restenosis or reintervention rates.
• The findings suggest that metformin may not be beneficial for preventing restenosis or reintervention in patients receiving lower extremity nDESs.
• Further research may be needed to explore other potential benefits or specific patient subgroups where metformin could be effective.